公开(公告)号：US20210162037A1

公开(公告)日：2021-06-03

申请号：US16098834

申请日：2017-05-04

Applicant: CureVac AG

Inventor： Edith JASNY ,  Susanne RAUCH ,  Kim Ellen SCHWENDT ,  Benjamin PETSCH ,  Karen SLOBOD

IPC: A61K39/145

Abstract: The present invention relates to mRNA sequences usable as mRNA-based vaccines against infections with influenza viruses. Additionally, the present invention relates to a composition comprising the mRNA sequences and the use of the mRNA sequences or the composition for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of influenza virus infections. The present invention further describes a method of treatment or prophylaxis of infections with influenza virus using the mRNA sequences.

公开(公告)号：US20170326225A1

公开(公告)日：2017-11-16

申请号：US15536595

申请日：2015-12-16

Applicant: CureVac AG

Inventor： Susanne RAUCH ,  Edith JASNY

IPC: A61K39/12 ,  C07K14/005 ,  C12N7/00 ,  A61K39/00

CPC classification number: A61K39/12 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/575 ,  A61K2039/70 ,  C07K14/005 ,  C12N7/00 ,  C12N2760/14134 ,  C12N2760/14234 ,  C12N2830/50

Abstract: The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein derived from the glycoprotein (GP) and/or the matrix protein 40 (VP40) and/or the nucleoprotein (NP) of a virus of the genus Ebolavirus or Marburgvirus or a fragment, variant or derivative thereof. Additionally, the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein derived from the glycoprotein (GP) and/or the matrix protein 40 (VP40) and/or the nucleoprotein (NP) of a virus of the genus Ebolavirus or Marburgvirus or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of Ebolavirus or Marburgvirus infections. The present invention further describes a method of treatment or prophylaxis of Ebolavirus or Marburgvirus infections using the mRNA sequence.

公开(公告)号：US20190351047A1

公开(公告)日：2019-11-21

申请号：US16471541

申请日：2017-12-22

Applicant: CureVac AG

Inventor： Edith JASNY ,  Benjamin PETSCH

IPC: A61K39/155 ,  C07K14/005 ,  C12N7/00

Abstract: The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Henipavirus, particularly Hendra virus and/or Nipah virus or a disorder related to such an infection. In particular, the present invention concerns a Hendra virus and/or Nipah virus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.

公开(公告)号：US20210205434A1

公开(公告)日：2021-07-08

申请号：US15999469

申请日：2017-02-17

Applicant: CureVac AG ,  Sanofi Pasteur SA

Inventor： Benjamin PETSCH ,  Edith JASNY ,  Yves GIRERO-CHAMBAZ

IPC: A61K39/12 ,  C07K14/005 ,  A61K39/385 ,  A61K47/64 ,  A61P31/14

Abstract: The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Zika virus or a disorder related to such an infection. In particular, the present invention concerns a Zika virus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.

公开(公告)号：US20190351044A1

公开(公告)日：2019-11-21

申请号：US16471544

申请日：2017-12-22

Applicant: CureVac AG

Inventor： Edith JASNY ,  Benjamin PETSCH

IPC: A61K39/12 ,  C07K14/005 ,  C12N7/00 ,  A61P31/14

Abstract: The present invention provides mRNAs usable as vaccines against lassa virus (LASV) infections. Further, the invention relates to (pharmaceutical) compositions and vaccines comprising said mRNAs and their use for treatment or prophylaxis of a lassa virus infection. The present invention further features a kit comprising the mRNAs, (pharmaceutical) compositions or vaccines and a method for treatment or prophylaxis of lassa virus infections using said mRNAs, pharmaceutical) compositions or vaccines.

公开(公告)号：US20210260178A1

公开(公告)日：2021-08-26

申请号：US17254847

申请日：2019-06-27

Applicant: CureVac AG

Inventor： Edith JASNY ,  Benjamin PETSCH ,  Hans Wolfgang GROSSE

IPC: A61K39/12 ,  C07K14/005 ,  C12N7/00 ,  A61P31/14

Abstract: The present invention is directed to RNA suitable for use in treatment and/or prophylaxis of an infection with Lassa virus (LASV) or of a disorder related to such an infection. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the RNA, compositions, and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the RNA, compositions and vaccines.

公开(公告)号：US20210069315A1

公开(公告)日：2021-03-11

申请号：US16772131

申请日：2018-12-12

Applicant: CureVac AG ,  Sanofi Pasteur

Inventor： Patrick BAUMHOF ,  Wolfgang GROSSE ,  Edith JASNY ,  Thomas KRAMPS ,  Daniel VOSS ,  Julia DANNENMAIER ,  Valérie LECOUTURIER ,  Yves GIRERD-CHAMBAZ

IPC: A61K39/12 ,  A61P31/14

Abstract: The present invention is directed to an artificial nucleic acid and to a polypeptide suitable for use in the treatment or prophylaxis of an infection with a flavivirus, in particular an infection with yellow fever virus or with dengue virus, or of a disorder related to such an infection. The present invention is also directed to a composition, preferably an immunogenic composition, comprising the artificial nucleic acid or the inventive polypeptide. In particular, the present invention concerns an immunogenic composition against a flavivirus, such as yellow fever virus or dengue virus. Further, the invention concerns a kit, particularly a kit of parts, comprising the artificial nucleic acid, polypeptide or (immunogenic) composition. The invention is further directed to a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptide, composition, in particular the first and second medical uses of the immunogenic composition according to the invention.

公开(公告)号：US20180312545A1

公开(公告)日：2018-11-01

申请号：US15774423

申请日：2016-11-09

Applicant: CureVac AG

Inventor： Patrick BAUMHOF ,  Susanne RAUCH ,  Aleksandra KOWALCZYK ,  Johannes LUTZ ,  Edith JASNY ,  Benjamin PETSCH ,  Andreas THESS ,  Thomas SCHLAKE ,  Mariola FOTIN-MLECZEK ,  Regina HEIDENREICH ,  Sandra LAZZARO ,  Fatma DÖNER ,  Wolfgang GROSSE

IPC: C07K14/005 ,  C07K14/205 ,  A61K39/145

CPC classification number: C12N15/00 ,  A61K39/12 ,  A61K2039/53 ,  C07K14/005 ,  C07K2319/00 ,  C12N2760/16122 ,  C12N2760/16134

Abstract: The present invention provides optimized nucleic acid molecules, methods for optimization of nucleic acid molecules and uses of optimized nucleic acid molecules. A modular design principle is provided that is suitable to generate a nucleic acid, particularly mRNA, which is tailored for a respective application. The nucleic acid molecules of the present invention can be obtained by the versatile combination of multiple modules on nucleic acid level. Such nucleic acid, e.g. mRNA, can be tailored by combining one or more modules, comprising (i) a nucleic acid moiety encoding a polypeptide of interest (e.g. a protein potentially producing a therapeutic outcome) and (ii) at least one further coding or non-coding nucleic acid moiety, e.g. selected among nucleic acid moieties encoding a polypeptide element, such as a secretory signal peptide (SSP), a multimerization element (dimerization, trimerization, tetramerization and oligomerization), a virus like particle (VLP) forming element, a transmembrane element, a dendritic cell targeting element, an immunological adjuvant element, an element promoting antigen presentation; a 2A peptide; a peptide linker element, elements that extend protein half-life, and/or any other polypeptide or protein. Non-coding nucleic acid moieties may be selected e.g. from the group comprising 3′-UTR, 5′-UTR, IRES element, miRNA moiety, histone stem loop, poly(C) sequence, polyadenylation signal, polyA-sequence. The optimized nucleic acid molecule can further be characterized by the presence of at least one modified nucleoside. The versatility of the present invention allows for rational design of a large variety of different nucleic acid molecules with desired properties.

公开(公告)号：US20210251898A1

公开(公告)日：2021-08-19

申请号：US17142731

申请日：2021-01-06

Applicant: CureVac AG ,  Acuitas Therapeutics Inc.

Inventor： Patrick BAUMHOF ,  Mariola FOTIN-MLECZEK ,  Regina HEIDENREICH ,  Michael J. HOPE ,  Edith JASNY ,  Sandra LAZZARO ,  Paulo Jia Ching LIN ,  Johannes LUTZ ,  Barbara MUI ,  Benjamin PETSCH ,  Susanne RAUCH ,  Kim Ellen SCHMIDT ,  Ying TAM

IPC: A61K9/127 ,  A61K47/69 ,  A61P37/02 ,  A61P31/16 ,  A61K9/19 ,  A61K31/7105 ,  A61K39/145 ,  A61K39/39 ,  A61K47/14 ,  A61K31/16 ,  A61K31/23 ,  A61K31/40

Abstract: The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and/or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.

公开(公告)号：US20210030864A1

公开(公告)日：2021-02-04

申请号：US16641064

申请日：2018-08-22

Applicant: CureVac AG

Inventor： Benjamin PETSCH ,  Edith JASNY

IPC: A61K39/12 ,  A61K9/00 ,  C12N7/00

Abstract: The present invention is directed to an artificial nucleic acid, particularly to an artificial RNA, and to polypeptides suitable for use in treatment or prophylaxis of an infection with a virus of the order Bunyavirales, particularly Severe fever with thrombocytopenia syndrome virus (SFTSV), Rift Valley fever virus (RVFV), or Crimean-Congo hemorrhagic fever virus (CCHFV), or a disorder related to such an infection. The present invention further concerns a Bunyavirales vaccine, particularly a SFTSV, RVFV, or CCHFV vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.